Orchard Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Orchard Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-17.9%
Buyback Yield
| Total Shareholder Yield | -17.9% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR
Jan 19Revenues Working Against Orchard Therapeutics plc's (NASDAQ:ORTX) Share Price
May 09
Is Orchard Therapeutics (NASDAQ:ORTX) A Risky Investment?
Mar 10Orchard Therapeutics: Gene Therapy For Rare Child Disease
Aug 19Orchard Therapeutics GAAP EPS of -$0.40 misses by $0.14, revenue of $4.37M beats by $1.19M
Aug 04Orchard Therapeutics: Shadow Of Former Glory
Jan 20Orchard Therapeutics: Cutting-Edge Science Beset With A Pioneer's Typical Hurdles
Aug 16Orchard Therapeutics (NASDAQ:ORTX) Has Debt But No Earnings; Should You Worry?
Jun 14What Is The Ownership Structure Like For Orchard Therapeutics plc (NASDAQ:ORTX)?
Feb 03Orchard Therapeutics appoints Braden Parker as chief commercial officer
Jan 29Orchard Therapeutics' OTL-200 wins FDA's RMAT status
Jan 14Orchard Therapeutics' OTL-103 US application for immunodeficiency disorder, pushed to 2022
Jan 12Is Orchard Therapeutics plc (NASDAQ:ORTX) Trading At A 26% Discount?
Jan 08Orchard Therapeutics' MLD gene therapy wins European nod
Dec 21Our View On Orchard Therapeutics
Dec 17Reflecting on Orchard Therapeutics' (NASDAQ:ORTX) Share Price Returns Over The Last Year
Dec 11Orchard's gene therapy shows encouraging action in a rare neurometabolic disorder study
Dec 08Orchard Therapeutics (ORTX) Investor Presentation - Slideshow
Nov 22Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if ORTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ORTX's dividend payments have been increasing.
Dividend Yield vs Market
| Orchard Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (ORTX) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.3% |
| Industry Average (Biotechs) | 2.3% |
| Analyst forecast (ORTX) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate ORTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ORTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate ORTX's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ORTX has not reported any payouts.